Differential gene expression data of commercial compounds used to assess the performance of human TeraTox assay

<p>The dataset supplements&nbsp;the publication `Optimization of the&nbsp;<em>TeraTox</em>&nbsp;assay for preclinical teratogenicity assessment`.&nbsp;</p> <ul> <li>2022-02-18-TeraTox-commercial-logFC.gct: log2FC matrix of genes by compounds (in concentration ranges)</li> <li>2022-02-18-TeraTox-commercial-pScore.gct: p-scores (log 10 transformed p-values with the sign of logFC) of genes by compounds</li> <li>2022-02-18-TeraTox-commercial-featureData.txt: feature annotation in TSV format</li> <li>2022-02-18-TeraTox-commercial-phenoData.txt: sample annotation in TSV format</li> <li>2021-06-10-gcGeneFactorAnno-withPositiveCoefs.tsv: gene membership of germ-layer factors, with germ-layer annotation and average expression in copies per million (cpm).</li> </ul> <p>Citation:&nbsp;Jaklin, Manuela, Jitao David Zhang, Nicole Sch&auml;fer, Nicole Clemann, Paul Barrow, Erich K&uuml;ng, Lisa Sach-Peltason, Claudia McGinnis, Marcel Leist, and Stefan Kustermann. &ldquo;Optimization of the TeraTox Assay for Preclinical Teratogenicity Assessment.&rdquo; <em>Toxicological Sciences</em> 188, no. 1 (July 1, 2022): 17&ndash;33. <a href="https://doi.org/10.1093/toxsci/kfac046">https://doi.org/10.1093/toxsci/kfac046</a>.</p>